Alert detail
LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
What changed
New LCD for prostate cancer risk-stratification impacts billing.
Who’s affected: Oncology billing teams · Effective: July 3, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 8 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.